Bob Langer-backed spinout shoots for $75M-plus IPO while biotech SPACs continue to rule on Wall Street
SQZ Biotech is looking to go public, squeezing its way onto a long list of biotechs to hit Wall Street this year.
The Watertown, MA-based biotech filed on Friday for a $75 million IPO to develop its cell therapies, now the main focus following a shift in priorities to pipeline building. Number 1 on its list of priorities is its Roche-partnered antigen presenting cell (APC) tech, which is currently in Phase I for HPV and solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.